Trial reportDermatology online journal2026
Facial rejuvenation with autologous exosomes released from preconditioned platelet-rich plasma using the meta cell technology system: A pilot study.
Trial report in Dermatology online journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Safe, noninvasive or minimally invasive techniques are available for facial rejuvenation. Recent research on exosomes has revealed promising avenues for new treatment options. Objective: This pilot study aimed to assess the efficacy of a facial rejuvenation treatment using autologous exosomes derived from preconditioned platelet-rich plasma with the Meta Cell Technology (MCT) System. Methods: A prospective, single-center, randomized, controlled pilot study was conducted in patients with facial aging signs. Participants received 3 sessions of autologous exosomes obtained using the MCT System. Outcomes were evaluated by measuring the subepidermal low-echogenic band (SLEB) using ultrasonography, capturing photographs with a compact stereophotogrammetric 3-dimensional imaging system, and obtaining patient-reported feedback on skin appearance and improvement. Results: Eleven patients (100% women; mean age, 57 ± 4.1 years; range, 51-65) were enrolled, and 9 (81.8%) completed the study. One month after the final treatment, ultrasonographic measurements demonstrated a mean reduction in SLEB thickness of 61.4% at the cheekbone and 39.35% at the cheek. Patient-reported outcomes indicated that 77.8% of participants perceived improvement in skin appearance. Conclusion: Treatment with autologous exosomes obtained using the MCT System was well tolerated and resulted in substantial facial rejuvenation, reducing SLEB thickness and enhancing patients' perceived skin quality.
Indexed as
Identifiers
42522478What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.